- Home
- ELAB vs ALLR Comparison
ELAB vs ALLR Comparison
Compare ELAB & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- ALLR
- Stock Information
- Founded
- ELAB 2020
- ALLR 2004
- Country
- ELAB United States
- ALLR United States
- Employees
- ELAB N/A
- ALLR N/A
- Industry
- ELAB
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- ALLR Health Care
- Exchange
- ELAB Nasdaq
- ALLR Nasdaq
- Market Cap
- ELAB 6.6M
- ALLR 6.0M
- IPO Year
- ELAB 2023
- ALLR N/A
- Fundamental
- Price
- ELAB $1.65
- ALLR $0.95
- Analyst Decision
- ELAB
- ALLR
- Analyst Count
- ELAB 0
- ALLR 0
- Target Price
- ELAB N/A
- ALLR N/A
- AVG Volume (30 Days)
- ELAB 4.6M
- ALLR 2.3M
- Earning Date
- ELAB 03-28-2025
- ALLR 03-07-2025
- Dividend Yield
- ELAB N/A
- ALLR N/A
- EPS Growth
- ELAB N/A
- ALLR N/A
- EPS
- ELAB N/A
- ALLR N/A
- Revenue
- ELAB $2,446,161.00
- ALLR N/A
- Revenue This Year
- ELAB N/A
- ALLR N/A
- Revenue Next Year
- ELAB N/A
- ALLR N/A
- P/E Ratio
- ELAB N/A
- ALLR N/A
- Revenue Growth
- ELAB 112.17
- ALLR N/A
- 52 Week Low
- ELAB $1.60
- ALLR $0.90
- 52 Week High
- ELAB $166.00
- ALLR $264.00
- Technical
- Relative Strength Index (RSI)
- ELAB 39.27
- ALLR 40.42
- Support Level
- ELAB $1.60
- ALLR $0.91
- Resistance Level
- ELAB $1.80
- ALLR $1.03
- Average True Range (ATR)
- ELAB 0.11
- ALLR 0.09
- MACD
- ELAB 0.04
- ALLR -0.02
- Stochastic Oscillator
- ELAB 15.66
- ALLR 13.88
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.